Rucaparib or Physician's Choice in Metastatic Prostate Cancer

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

Ipatasertib Plus Abiraterone: A New Potential Treatment for Metastatic Castration-Resistant Prostate Cancer With PTEN Loss - Cancer Therapy Advisor

Rucaparib or physician's choice in metastatic prostate cancer -ORCA

Rucaparib Bests Physician's Choice in Metastatic Castration-Resistant Prostate Cancer - Cancer Therapy Advisor

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Frontiers Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer

PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC

When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials - ScienceDirect

ESMO 2018: Preliminary Results From TRITON2: A Phase II Study of Rucaparib in Patients with mCRPC Associated with Homologous Recombination Repair Gene Alterations